Funding from SOSE to Establish UK GMP Manufacturing Facility
Filed with ASX · · 3 pages · English
Bioxyne Limited (ASX: BXN) (“Bioxyne” or “the Company”), through its subsidiary Breathe Life Sciences UK Ltd (BLSUK), is pleased to advise that it has received ~£850,000 in funding commitments from South of Scotland Enterprise, the economic development agency for the South of Scotland, to fit-out and establish its UK medicinal cannabis manufacturing and distribution facility. Key Highlights • The
Earlier from Bioxyne
- BLS to Manufacture and Distribute Curaleaf International MID
- Presentation on FY2025 Quarter 1 Results
- Initial German Purchase Orders and Import Permits
- BXN Full Year 2026 Guidance
- FY2025 Results Presentation
Later from Bioxyne
- Supply Agreement Secured - Central American Cannabis Markets
- Quarterly Activities/Appendix 4C Cash Flow Report
- Appendix 4C Revised
- Presentation Results Q2 FY2026
- Half Yearly Report and Accounts
Follow Bioxyne into a list and get an email when it puts out news.
Follow Bioxyne